drugset / Trial / NCT03596567

Glasdegib Renal Impairment Study

NCT03596567

Phase 1 Completed 18 enrolled Pfizer
RandomizedParallel-groupOpen-labelBasic science

Summary

The goal of this study is to administer single dose (100 mg) glasdegib tablet to subjects with normal, moderate and severe renal impairment and estimate the effect, if any, of this renal impairment on glasdegib pharmacokinetics.

Timeline

Start
2018-05-17
Primary completion
2018-08-28
Completion
2018-09-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Glasdegib Small molecule 100 mg Oral